Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00495391 · ClinicalTrials.gov registry record · Phase 2
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
A Phase 2 study, sponsored by Romark Laboratories L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00495391 is a Phase 2 study that has completed, run by Romark Laboratories L.C.. The registered enrollment target is 64 participants.
The verdict
NCT00495391, a Phase 2 study, has completed, sponsored by Romark Laboratories L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to treatment with peginterferon and ribavirin.
Interventions
- DRUG Placebo
- DRUG Ribavirin
- DRUG Nitazoxanide
- BIOLOGICAL Peginterferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00495391
The ClinicalTrials.gov registry entry for NCT00495391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Romark Laboratories L.C., which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00495391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00495391 about?
NCT00495391 is a clinical study titled "Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C". The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to treatment with peginterferon and ribavirin.
What is the current status of trial NCT00495391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2007-07. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00495391?
The interventions under investigation include: Placebo (DRUG), Ribavirin (DRUG), Nitazoxanide (DRUG), Peginterferon alfa-2a (BIOLOGICAL).
Who is sponsoring clinical trial NCT00495391?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.